One such blocker is anakinra, a recombinant, non-glycosylated form of hIL-1Ra with an N-terminal methionine that was approved for clinical use in 2001 for rheumatoid arthritis (RA) and has since been used in other inflammatory conditions, such as cryopyrin-associated periodic syndromes (CAPS) and systemic idiopathic juvenile arthritis 7, 8. The gene discussed is NLRP3; the disease is rheumatoid arthritis.